The number of cardiovascular events was increased in patients given anacetrapib compared with those given placebo ( @ -LSB- @ % -RSB- of @ vs none -LSB- @ % -RSB- of @ ; p = @ ) , but the proportion with adverse events leading to discontinuation was similar ( @ -LSB- @ % -RSB- of @ vs five -LSB- @ % -RSB- of @ ) .